Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
CA 2490863 A1 · Owner: Wang, Zhuo · Inventors: Frolkis, Maria; Majumdar, Anish Sen; Ferber, Iris A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been discovered that a robust and therapeutic anti-cancer response can be generated by immunizing with a xenogeneic form of the enzyme telomerase reverse transcriptase (TERT). Cancer subjects are multiply immunized with TERT from another species-either in protein form or with a TERT expression vector. , Presence of the xenogeneic components apparently overcomes natural immunotolerance to self-antigen. The response can be focused by simultaneous or subsequent immunization with isogenic TERT. As a result the immune system , generates T lymphocytes that are cytotoxic for virtually any cancer cell by , virtue of TERT expressed due to malignant transformation. The anti-tumor …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.